查看購物車
  • Simplified Chinese
  • English
  • Japanese
細胞及基因治療藥物傳遞市場－全球及區域分析：依治療類型、傳遞方式及區域－分析與預測（2025-2035）
市場調查報告書
商品編碼
1808110

細胞及基因治療藥物傳遞市場－全球及區域分析：依治療類型、傳遞方式及區域－分析與預測（2025-2035）

Cell and Gene Therapy Drug Delivery Market - A Global and Regional Analysis: Focus on Therapy Types, Delivery Methods, Country, and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 110 Pages | 商品交期: 1-5個工作天內

價格

全球細胞和基因治療藥物傳輸市場 - 分析與預測（2025-2035）

細胞和基因治療藥物傳遞是一種專門的方法，用於將含有活細胞或基因改造基因的複雜治療方法注射到患者體內。

這個輸送過程對於確保這些先進的療法有效且安全地引入目標細胞和組織至關重要，這些療法通常涉及修改患者的遺傳物質或提供新細胞來修復或替換受損組織。

藥物輸送系統領域涵蓋預填充注射器、輸液幫浦、注射器和專用套管等設備，旨在滿足這些先進療法的獨特需求。這些系統對於克服治療的微妙性所帶來的挑戰至關重要，例如確保細胞和基因的穩定性、防止免疫排斥以及標靶化體內的適當部位。

整體而言，細胞和基因治療藥物傳遞是推動精準醫療的重要組成部分，為治療遺傳疾病、癌症和其他以前難以治療的嚴重帶來了新的希望。

細胞和基因療法藥物傳輸市場的主要驅動力之一是慢性病和遺傳疾病（尤其是癌症、糖尿病和罕見遺傳疾病）的盛行率不斷上升。隨著這些疾病的日益普遍，對能夠提供有針對性且有效治療方法的先進治療方法的需求也日益成長。雖然細胞和基因療法已成為突破性的解決方案，但它們的成功在很大程度上取決於創新的藥物傳輸裝置，這些裝置能夠確保精準給藥、最佳劑量並改善患者預後。慢性疾病患者數量的快速成長不僅刺激了這些治療方法的採用，也加速了專用輸送裝置的開發和廣泛應用，推動了市場的強勁成長。

細胞和基因治療藥物傳輸市場面臨的主要挑戰之一是高昂的製造和治療成本。細胞和基因治療藥物的製造涉及複雜的活細胞和基因改造過程，需要專用設備、高技能勞動力以及大量的研發投入。這些治療方法通常個性化，這增加了其成本。此外，用於實施這些治療方法的專用藥物輸送設備，例如輸液泵、預填充式注射器和專用注射器，也導致了治療總成本的居高不下。

這項挑戰限制了這些治療方法的可及性，尤其對於資源匱乏地區和保險不足的患者而言。高昂的治療費用可能會阻礙這些治療方法的廣泛應用，並減緩其融入全球醫療保健體系的速度。克服這些經濟障礙對於讓更多患者能夠獲得細胞和基因療法至關重要。

全球細胞和基因治療藥物輸送市場競爭激烈，幾個主要企業推動創新和市場成長。諾華、輝瑞、安進公司、碧迪公司、吉利德科學（凱特製藥）、百時美施貴寶和強生等主要企業公司在開發和商業化用於細胞和基因治療的先進藥物輸送系統方面處於領先地位。

這些公司正在大力投資研發，以開發更有效率、可擴展且更適合患者的給藥方法，旨在提高這些創新療法的可及性和有效性。

細胞和基因治療藥物傳輸市場細分：

細分 1：依治療類型

  • 細胞療法
  • 基因治療

細分 2：依交付方式

  • 體內
  • 體外

細分3：依地區

  • 北美洲
  • 歐洲
  • 亞太地區

全球細胞和基因治療藥物傳輸市場最重要的新興趨勢之一是血液生物標記檢測在阿茲海默症早期檢測中的進展和廣泛應用。這些檢測提供了一種侵入性較小、經濟高效且可擴展的替代方案，可取代腦脊髓液 (CSF) 分析和正子斷層掃描 (PET) 等傳統方法。尤其是羅氏的 Elecsys pTau217 等血液檢測已證明其診斷準確性可與 PET 和 CSF 檢測相媲美，標誌著臨床診斷領域的一個重要里程碑。這些檢測能夠在阿茲海默症出現嚴重認知能力下降之前進行早期檢測，為早期療育提供了重要機會。

此外，血液診斷技術在臨床試驗中發展勢頭強勁，為確定合適的緩解疾病治療候選藥物提供了更便捷的方法。這一趨勢不僅提高了阿茲海默症診斷的準確性，也使檢測更加經濟實惠、便捷易得，這對於全球推廣至關重要，尤其是在醫療資源匱乏的地區。隨著這些技術的不斷發展和獲得監管部門的核准，它們有望徹底改變阿茲海默症的檢測和管理，最終改善患者的預後。

本報告研究了全球細胞和基因治療藥物輸送市場，提供了市場概述、依治療類型、輸送方式和地區分類的趨勢，以及參與市場的公司概況。

目錄

執行摘要

第1章全球細胞和基因治療藥物傳輸市場：產業展望

  • 介紹
  • 市場趨勢
  • 法律規範
  • 臨床試驗分析
  • 市場動態

2. 全球細胞和基因治療藥物傳輸市場（依治療類型），2023-2035

  • 細胞療法
  • 基因治療

3. 全球細胞與基因治療藥物傳遞市場（傳遞方式），2023-2035

  • 體內
  • 體外

4. 2023-2035年全球細胞及基因治療藥物傳遞市場（依地區）

  • 北美洲
  • 歐洲
  • 亞太地區

5. 全球細胞和基因治療藥物傳輸市場：競爭格局和公司概況

  • 關鍵策略和發展
  • 公司簡介
    • Amgen Inc.
    • Bausch & Lomb Incorporated
    • Becton, Dickinson and Company
    • Bluebird bio, Inc.
    • Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)
    • Dendreon Pharmaceuticals LLC
    • Helixmith Co., Ltd (ViroMed Co., Ltd)
    • Gilead Sciences (Kite Pharma)
    • Kolon TissueGene, Inc.
    • Novartis AG
    • Orchard Therapeutics plc
    • Pfizer Inc.
    • Renova Therapeutics
    • Vericel Corporation

第6章調查方法

Product Code: BHL3239SA

Global Cell and Gene Therapy Drug Delivery Market, Analysis and Forecast: 2025-2035

Cell and gene therapy drug delivery is a specialized method used to administer complex therapeutic treatments, including living cells and genetically modified genes, into a patient's body. This delivery process is crucial for ensuring that these advanced therapies are effectively and safely introduced to the targeted cells or tissues. The therapies often involve modifying a patient's genetic material or providing new cells to repair or replace damaged tissues.

The drug delivery systems in this field include devices like pre-filled syringes, infusion pumps, injectors, and specialized cannulas, designed to meet the specific needs of these advanced therapies. These systems are critical for overcoming the challenges posed by the delicate nature of the therapies, such as ensuring the stability of cells and genes, preventing immune rejection, and targeting the right areas of the body.

Overall, cell and gene therapy drug delivery is an essential component of advancing precision medicine, offering new hope for the treatment of genetic disorders, cancers, and other severe diseases that were previously difficult to treat.

One of the key drivers of the cell and gene therapy drug delivery market is the increasing prevalence of chronic and genetic disorders, particularly cancer, diabetes, and rare genetic diseases. As these conditions become more widespread, there is a growing demand for advanced therapies that can offer targeted and effective treatment options. Cell and gene therapies have emerged as transformative solutions, and their success relies heavily on innovative drug delivery devices that ensure precise administration, optimal dosage, and improved patient outcomes. This surge in chronic disease cases not only fuels the adoption of these therapies but also accelerates the development and deployment of specialized delivery devices, thereby driving robust market growth

One of the primary challenges in the cell and gene therapy drug delivery market is the high cost of manufacturing and treatment. The production of cell and gene therapies involves complex processes, including the modification of living cells or genes, which requires specialized equipment, highly skilled labor, and significant research and development. These therapies are often personalized, adding to the cost. Additionally, the specialized drug delivery devices required for administering these therapies, such as infusion pumps, pre-filled syringes, and specialized injectors, also contribute to the high overall treatment cost.

This challenge limits the accessibility of these therapies, especially in low-resource settings or for patients without adequate insurance coverage. The high costs can hinder the widespread adoption of these treatments and slow down their integration into global healthcare systems. Overcoming these financial barriers is crucial to ensuring that cell and gene therapies reach a broader patient population.

The global cell and gene therapy drug delivery market is highly competitive, with several key players driving innovation and market growth. Leading companies such as Novartis, Pfizer, Amgen Inc., Becton, Dickinson and Company, Gilead Sciences (Kite Pharma), Bristol Myers Squibb, and Johnson & Johnson are at the forefront of developing and commercializing advanced drug delivery systems for cell and gene therapies.

These companies are investing heavily in research and development to create more efficient, scalable, and patient-friendly delivery methods, aiming to enhance the accessibility and effectiveness of these transformative treatments.

Cell and Gene Therapy Drug Delivery Market Segmentation:

Segmentation 1: by Therapy Types

  • Cell Therapy
  • Gene Therapy

Segmentation 2: by Delivery Methods

  • In Vivo
  • Ex Vivo

Segmentation 3: by Region

  • North America
  • Europe
  • Asia-Pacific

One of the most significant emerging trends in the global cell and gene therapy drug delivery market is the advancement and widespread adoption of blood-based biomarker tests for the early detection of Alzheimer's disease. These tests offer a less invasive, cost-effective, and scalable alternative to traditional methods like cerebrospinal fluid (CSF) analysis and positron emission tomography (PET) scans. Notably, blood-based tests such as Roche's Elecsys pTau217 have demonstrated diagnostic accuracy comparable to PET scans and CSF assays, marking a major milestone in clinical diagnostics. These tests enable earlier detection of Alzheimer's, often before significant cognitive decline occurs, providing critical opportunities for early intervention.

Furthermore, blood-based diagnostics are gaining momentum in clinical trials, offering a more accessible way to identify suitable candidates for disease-modifying treatments. This trend is not only increasing the accuracy of Alzheimer's diagnoses but also improving the affordability and accessibility of testing, which is crucial for global adoption, particularly in underserved regions. As these technologies continue to evolve and gain regulatory approval, they are expected to revolutionize Alzheimer's disease detection and management, ultimately leading to better outcomes for patients.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Cell and Gene Therapy Drug Delivery Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Clinical Trial Analysis
  • 1.5 Market Dynamics
    • 1.5.1 Impact Analysis
    • 1.5.2 Market Drivers
    • 1.5.3 Market Challenges
    • 1.5.4 Market Opportunities

2. Global Cell and Gene Therapy Drug Delivery Market (Therapy Types), ($Billion), 2023-2035

  • 2.1 Cell Therapy
  • 2.2 Gene Therapy

3. Global Cell and Gene Therapy Drug Delivery Market (Delivery Methods), ($Billion), 2023-2035

  • 3.1 In Vivo
  • 3.2 Ex Vivo

4. Global Cell and Gene Therapy Drug Delivery Market (Region), ($Billion), 2023-2035

  • 4.1 North America
    • 4.1.1 Key Findings
    • 4.1.2 Market Dynamics
    • 4.1.3 Market Sizing and Forecast
      • 4.1.3.1 North America Cell and Gene Therapy Drug Delivery Market, by Country
        • 4.1.3.1.1 U.S.
  • 4.2 Europe
    • 4.2.1 Key Findings
    • 4.2.2 Market Dynamics
    • 4.2.3 Market Sizing and Forecast
      • 4.2.3.1 Europe Cell and Gene Therapy Drug Delivery Market, by Country
        • 4.2.3.1.1 Germany
        • 4.2.3.1.2 U.K.
        • 4.2.3.1.3 France
        • 4.2.3.1.4 Italy
  • 4.3 Asia Pacific
    • 4.3.1 Key Findings
    • 4.3.2 Market Dynamics
    • 4.3.3 Market Sizing and Forecast
      • 4.3.3.1 Asia Pacific Cell and Gene Therapy Drug Delivery Market, by Country
        • 4.3.3.1.1 China
        • 4.3.3.1.2 Japan

5. Global Cell and Gene Therapy Drug Delivery Market: Competitive Landscape and Company Profiles

  • 5.1 Key Strategies and Development
    • 5.1.1 Mergers and Acquisitions
    • 5.1.2 Synergistic Activities
    • 5.1.3 Business Expansions and Funding
    • 5.1.4 Product Launches and Approvals
    • 5.1.5 Other Activities
  • 5.2 Company Profiles
    • 5.2.1 Amgen Inc.
      • 5.2.1.1 Overview
      • 5.2.1.2 Top Products / Product Portfolio
      • 5.2.1.3 Top Competitors
      • 5.2.1.4 Target Customers/End-Users
      • 5.2.1.5 Key Personnel
      • 5.2.1.6 Analyst View
    • 5.2.2 Bausch & Lomb Incorporated
      • 5.2.2.1 Overview
      • 5.2.2.2 Top Products / Product Portfolio
      • 5.2.2.3 Top Competitors
      • 5.2.2.4 Target Customers/End-Users
      • 5.2.2.5 Key Personnel
      • 5.2.2.6 Analyst View
    • 5.2.3 Becton, Dickinson and Company
      • 5.2.3.1 Overview
      • 5.2.3.2 Top Products / Product Portfolio
      • 5.2.3.3 Top Competitors
      • 5.2.3.4 Target Customers/End-Users
      • 5.2.3.5 Key Personnel
      • 5.2.3.6 Analyst View
    • 5.2.4 Bluebird bio, Inc.
      • 5.2.4.1 Overview
      • 5.2.4.2 Top Products / Product Portfolio
      • 5.2.4.3 Top Competitors
      • 5.2.4.4 Target Customers/End-Users
      • 5.2.4.5 Key Personnel
      • 5.2.4.6 Analyst View
    • 5.2.5 Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)
      • 5.2.5.1 Overview
      • 5.2.5.2 Top Products / Product Portfolio
      • 5.2.5.3 Top Competitors
      • 5.2.5.4 Target Customers/End-Users
      • 5.2.5.5 Key Personnel
      • 5.2.5.6 Analyst View
    • 5.2.6 Dendreon Pharmaceuticals LLC
      • 5.2.6.1 Overview
      • 5.2.6.2 Top Products / Product Portfolio
      • 5.2.6.3 Top Competitors
      • 5.2.6.4 Target Customers/End-Users
      • 5.2.6.5 Key Personnel
      • 5.2.6.6 Analyst View
    • 5.2.7 Helixmith Co., Ltd (ViroMed Co., Ltd)
      • 5.2.7.1 Overview
      • 5.2.7.2 Top Products / Product Portfolio
      • 5.2.7.3 Top Competitors
      • 5.2.7.4 Target Customers/End-Users
      • 5.2.7.5 Key Personnel
      • 5.2.7.6 Analyst View
    • 5.2.8 Gilead Sciences (Kite Pharma)
      • 5.2.8.1 Overview
      • 5.2.8.2 Top Products / Product Portfolio
      • 5.2.8.3 Top Competitors
      • 5.2.8.4 Target Customers/End-Users
      • 5.2.8.5 Key Personnel
      • 5.2.8.6 Analyst View
    • 5.2.9 Kolon TissueGene, Inc.
      • 5.2.9.1 Overview
      • 5.2.9.2 Top Products / Product Portfolio
      • 5.2.9.3 Top Competitors
      • 5.2.9.4 Target Customers/End-Users
      • 5.2.9.5 Key Personnel
      • 5.2.9.6 Analyst View
    • 5.2.10 Novartis AG
      • 5.2.10.1 Overview
      • 5.2.10.2 Top Products / Product Portfolio
      • 5.2.10.3 Top Competitors
      • 5.2.10.4 Target Customers/End-Users
      • 5.2.10.5 Key Personnel
      • 5.2.10.6 Analyst View
    • 5.2.11 Orchard Therapeutics plc
      • 5.2.11.1 Overview
      • 5.2.11.2 Top Products / Product Portfolio
      • 5.2.11.3 Top Competitors
      • 5.2.11.4 Target Customers/End-Users
      • 5.2.11.5 Key Personnel
      • 5.2.11.6 Analyst View
    • 5.2.12 Pfizer Inc.
      • 5.2.12.1 Overview
      • 5.2.12.2 Top Products / Product Portfolio
      • 5.2.12.3 Top Competitors
      • 5.2.12.4 Target Customers/End-Users
      • 5.2.12.5 Key Personnel
      • 5.2.12.6 Analyst View
    • 5.2.13 Renova Therapeutics
      • 5.2.13.1 Overview
      • 5.2.13.2 Top Products / Product Portfolio
      • 5.2.13.3 Top Competitors
      • 5.2.13.4 Target Customers/End-Users
      • 5.2.13.5 Key Personnel
      • 5.2.13.6 Analyst View
    • 5.2.14 Vericel Corporation
      • 5.2.14.1 Overview
      • 5.2.14.2 Top Products / Product Portfolio
      • 5.2.14.3 Top Competitors
      • 5.2.14.4 Target Customers/End-Users
      • 5.2.14.5 Key Personnel
      • 5.2.14.6 Analyst View

6. Research Methodology

List of Figures

  • Figure: Global Cell and Gene Therapy Drug Delivery Market (by Therapy Types), $Billion, 2024 and 2035
  • Figure: Global Cell and Gene Therapy Drug Delivery Market (by Delivery Methods), $Billion, 2024 and 2035
  • Figure: Global Cell and Gene Therapy Drug Delivery Market (by Region), $Billion, 2024 and 2035
  • Figure: Global Cell and Gene Therapy Drug Delivery Market Key Trends, Analysis

List of Tables

  • Table: Global Cell and Gene Therapy Drug Delivery Market Dynamics, Impact Analysis
  • Table: Global Cell and Gene Therapy Drug Delivery Market (by Region), $Billion, 2024-2035